ArticleFrontiers in pharmacology2024

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.

Hongfu Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.